Latest & greatest articles for copd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd

62. Home-based maintenance tele-rehabilitation reduces the risk for acute exacerbations of COPD, hospitalisations and emergency department visits

Home-based maintenance tele-rehabilitation reduces the risk for acute exacerbations of COPD, hospitalisations and emergency department visits 28546268 2017 05 26 2017 05 26 1399-3003 49 5 2017 May The European respiratory journal Eur. Respir. J. Home-based maintenance tele-rehabilitation reduces the risk for acute exacerbations of COPD, hospitalisations and emergency department visits. 1602129 10.1183/13993003.02129-2016 Pulmonary rehabilitation (PR) remains grossly underutilised by suitable (...) patients worldwide. We investigated whether home-based maintenance tele-rehabilitation will be as effective as hospital-based maintenance rehabilitation and superior to usual care in reducing the risk for acute chronic obstructive pulmonary disease (COPD) exacerbations, hospitalisations and emergency department (ED) visits.Following completion of an initial 2-month PR programme this prospective, randomised controlled trial (between December 2013 and July 2015) compared 12 months of home-based

EvidenceUpdates2017

63. Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events

Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events 28536251 2017 05 24 2017 05 24 1399-3003 49 5 2017 May The European respiratory journal Eur. Respir. J. Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events. 1602245 10.1183/13993003.02245-2016 The cardiovascular risk of concurrently using long-acting β2-agonists (LABAs) and anticholinergics (LAMAs) in COPD is uncertain. We assessed the comparative (...) cardiovascular and cerebrovascular safety of adding a second long-acting bronchodilator in patients with COPD.We identified a cohort of COPD patients, new users of LABA or the LAMA tiotropium during 2002-2012, from the UK Clinical Practice Research Datalink. Using high-dimensional propensity scores, each patient adding a second bronchodilator was matched with a patient who remained on monotherapy. Patients were followed for 1 year for the occurrence of acute myocardial infarction (AMI), stroke, heart

EvidenceUpdates2017

64. Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD

Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD 28424359 2017 04 20 2017 04 20 1399-3003 49 4 2017 Apr The European respiratory journal Eur. Respir. J. Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD. 1601348 10.1183/13993003.01348-2016 Two replicate, double-blind, 6-week, incomplete-crossover studies (MORACTO 1 and 2) assessed the effects of tiotropium/olodaterol on inspiratory capacity

EvidenceUpdates2017

65. Colistin for Prophylactic Use in Non-Cystic Fibrosis Bronchiectasis or COPD with Exacerbations: A Review of Clinical and Cost-Effectiveness and Guidelines

Colistin for Prophylactic Use in Non-Cystic Fibrosis Bronchiectasis or COPD with Exacerbations: A Review of Clinical and Cost-Effectiveness and Guidelines Colistin for Prophylactic Use in Non-Cystic Fibrosis Bronchiectasis or COPD with Exacerbations: A Review of Clinical and Cost-Effectiveness and Guidelines | CADTH.ca Find the information you need Colistin for Prophylactic Use in Non-Cystic Fibrosis Bronchiectasis or COPD with Exacerbations: A Review of Clinical and Cost-Effectiveness (...) and Guidelines Colistin for Prophylactic Use in Non-Cystic Fibrosis Bronchiectasis or COPD with Exacerbations: A Review of Clinical and Cost-Effectiveness and Guidelines Published on: June 27, 2017 Project Number: RC0896-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of colistin for the prophylactic treatment of adults with either non-cystic fibrosis bronchiectasis or patients

Canadian Agency for Drugs and Technologies in Health - Rapid Review2017

66. Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD).

Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD). BACKGROUND: People with chronic obstructive pulmonary disease (COPD) have poor quality of life, reduced survival, and accelerated decline in lung function, especially associated with acute exacerbations, leading to high healthcare costs. Long-acting bronchodilators are the mainstay of treatment for symptomatic improvement, and umeclidinium is one of the new long-acting muscarinic antagonists (...) approved for treatment of patients with stable COPD. OBJECTIVES: To assess the efficacy and safety of umeclidinium bromide versus placebo for people with stable COPD. SEARCH METHODS: We searched the Cochrane Airways Group Specialised Register (CAGR), ClinicalTrials.gov, the World Health Organization (WHO) trials portal, and the GlaxoSmithKline (GSK) Clinical Study Register, using prespecified terms, as well as the reference lists of all identified studies. Searches are current to April 2017. SELECTION

Cochrane2017

67. Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical Trial.

Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical Trial. Importance: Outcomes after exacerbations of chronic obstructive pulmonary disease (COPD) requiring acute noninvasive ventilation (NIV) are poor and there are few treatments to prevent hospital readmission and death. Objective: To investigate the effect of home NIV plus oxygen on time to readmission or death in patients (...) with persistent hypercapnia after an acute COPD exacerbation. Design, Setting, and Participants: A randomized clinical trial of patients with persistent hypercapnia (Paco2 >53 mm Hg) 2 weeks to 4 weeks after resolution of respiratory acidemia, who were recruited from 13 UK centers between 2010 and 2015. Exclusion criteria included obesity (body mass index [BMI] >35), obstructive sleep apnea syndrome, or other causes of respiratory failure. Of 2021 patients screened, 124 were eligible. Interventions

JAMA2017

69. Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk

Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk 28416587 2017 04 18 2017 04 18 1468-201X 2017 Apr 17 Heart (British Cardiac Society) Heart Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk. heartjnl-2016-310897 10.1136/heartjnl-2016-310897 Cardiovascular disease (CVD) and chronic obstructive pulmonary disease (COPD) often coexist. We assessed the effect (...) of inhaled COPD treatments on CVD outcomes and safety in patients with COPD and at heightened CVD risk. The SUMMIT (Study to Understand Mortality and MorbidITy) was a multicentre, randomised, double-blind, placebo-controlled, event-driven trial in 16 485 patients with moderate COPD who had or were at high risk of CVD. Here, we assessed the prespecified secondary endpoint of time to first on-treatment composite CVD event (CVD death, myocardial infarction, stroke, unstable angina or transient ischaemic

EvidenceUpdates2017

72. Oxygen Saturation Target of 88-92% in COPD: Evidence-based Medicine?

Oxygen Saturation Target of 88-92% in COPD: Evidence-based Medicine? Oxygen Saturation Target of 88-92% in COPD: Evidence-based Medicine? | Clinical Correlations Oxygen Saturation Target of 88-92% in COPD: Evidence-based Medicine? April 12, 2017 By Christopher V. Cosgriff Peer Reviewed The American College of Physicians (ACP) recommends supplemental long-term oxygen therapy (LTOT) in all patients who have severe resting hypoxemia, defined as a PaO 2 ≤55 mmHg or an SpO 2 ≤88%. In patients (...) , and no benefit for all secondary outcomes; the authors noted that the consistency of the null result across all outcomes strengthens their findings. It can thus be concluded from these studies that LTOT provides a mortality benefit in severely hypoxemic patients with COPD, but does not improve mortality in those with mild-to-moderate hypoxemia. These trials do not indicate an optimal target range for supplemental oxygenation. The currently accepted oxygen saturation target of 88%-92% is an attempt to provide

Clinical Correlations2017

73. Cardiopulmonary response during whole-body vibration training in patients with severe COPD

Cardiopulmonary response during whole-body vibration training in patients with severe COPD 28326310 2018 11 13 2312-0541 3 1 2017 Jan ERJ open research ERJ Open Res Cardiopulmonary response during whole-body vibration training in patients with severe COPD. 00101-2016 10.1183/23120541.00101-2016 Several studies in patients with chronic obstructive pulmonary disease (COPD) have shown that whole-body vibration training (WBVT) has beneficial effects on exercise capacity. However, the acute (...) cardiopulmonary demand during WBVT remains unknown and was therefore investigated in this study. Ten patients with severe COPD (forced expiratory volume in 1 s: 38±8% predicted) were examined on two consecutive days. On day one, symptom-limited cardiopulmonary exercise testing was performed on a cycle ergometer. The next day, six bouts of repeated squat exercises were performed in random order for one, two or three minutes either with or without WBVT while metabolic demands were simultaneously measured. Squat

ERJ open research2017 Full Text: Link to full Text with Trip Pro

74. Community pharmacy COPD services: what do researchers and policy makers need to know?

Community pharmacy COPD services: what do researchers and policy makers need to know? 29354551 2018 11 13 2230-5254 6 2017 Integrated pharmacy research & practice Integr Pharm Res Pract Community pharmacy COPD services: what do researchers and policy makers need to know? 53-59 10.2147/IPRP.S105279 COPD is a leading cause of morbidity and mortality across the world and is responsible for a disproportionate use of health care resources. It is a progressive condition that is largely caused (...) by smoking. Identification of early stage COPD provides an opportunity for interventions, such as smoking cessation, which prevent its progression. Once diagnosed, ongoing support services potentially provide an opportunity to assist the patient in managing their condition and working more closely with the rest of the primary care team. While there are a number of robust studies which have demonstrated the role which pharmacists could undertake to identify and prevent disease progression, adoption

Integrated pharmacy research & practice2017 Full Text: Link to full Text with Trip Pro

75. β-blockers in exacerbations of COPD: feasibility of a randomised controlled trial.

β-blockers in exacerbations of COPD: feasibility of a randomised controlled trial. 28154818 2017 02 03 2017 02 24 3 1 2017 Jan ERJ open research ERJ Open Res β-blockers in exacerbations of COPD: feasibility of a randomised controlled trial. 00090-2016 10.1183/23120541.00090-2016 A feasibility randomised controlled trial of β-blockers in acute exacerbations of COPD http://ow.ly/lVcy305B36D. Chang Catherina L CL Respiratory Research Unit, Dept of Respiratory Medicine, Waikato Hospital, Hamilton

ERJ open research2017 Full Text: Link to full Text with Trip Pro

76. Management of severe COPD.

Management of severe COPD. Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide, and the burden of the disorder will continue to increase over the next 20 years despite medical intervention. Apart from smoking cessation, no approach or agent affects the rate of decline in lung function and progression of the disease. Especially in the later phase, COPD is a multicomponent disorder, and various integrated intervention strategies are needed as part

Lancet2017

77. Burden and clinical features of chronic obstructive pulmonary disease (COPD).

Burden and clinical features of chronic obstructive pulmonary disease (COPD). Chronic obstructive pulmonary disease (COPD) is a major cause of chronic morbidity and mortality and represents a substantial economic and social burden throughout the world. It is the fifth leading cause of death worldwide and further increases in its prevalence and mortality are expected in the coming decades. The substantial morbidity associated with COPD is often underestimated by health-care providers (...) and patients; likewise, COPD is frequently underdiagnosed and undertreated. COPD develops earlier in life than is usually believed. Tobacco smoking is by far the major risk for COPD and the prevalence of the disease in different countries is related to rates of smoking and time of introduction of cigarette smoking. Contribution of occupational risk factors is quite small, but may vary depending on a country's level of economic development. Severe deficiency for alpha-1-antitrypsin is rare and the impact

Lancet2017

79. In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids

In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids | BMJ Evidence-Based Medicine We use cookies to improve our service (...) name or password? You are here In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids Article Text Commentary General medicine In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids

Evidence-Based Medicine (Requires free registration)2017